BPI-2361 is high effective self-developed KRAS inhibitor. KRAS gene is the most frequently mutated oncogene in human cancers, which is about 20-30% of human cancers. Based on its wide patient distribution, the potential market for KRAS is comparable to PD-1. The incidence of KRASG12C in ...
VACCINATION OR IMMUNIZATION USING A PRIME-BOOST REGIMEN AGAINST BRSV, BHV-1, BVDV, BPI-3 来自 百度文库 喜欢 0 阅读量: 25 申请(专利)号: AU20030215835 申请日期: 2003-02-19 公开/公告号: AU2003215835A1 公开/公告日期: 2004-09-09 申请(专利权)人: MERIAL 发明人: AUDONNET Jean-...